MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
25.60
-1.16
-4.33%
After Hours: 25.66 +0.06 +0.23% 19:45 12/17 EST
OPEN
26.80
PREV CLOSE
26.76
HIGH
27.87
LOW
25.53
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
35.25
52 WEEK LOW
13.53
MARKET CAP
2.60B
P/E (TTM)
-5.7724
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BEAM last week (1208-1212)?
Weekly Report · 2d ago
Beam Therapeutics Gains $255M from Orbital Acquisition
TipRanks · 6d ago
Beam Therapeutics Nets $255 Million From Orbital Therapeutics Sale
Reuters · 6d ago
Efficient Sickle Cell Base-Editing Data Might Change The Case For Investing In Beam Therapeutics (BEAM)
Simply Wall St · 6d ago
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?
NASDAQ · 12/10 16:30
Beam Therapeutics’ Promising BEACON Trial and Advanced Manufacturing Boost Buy Rating
TipRanks · 12/09 13:55
Beam Therapeutics (BEAM) Receives a Buy from Wedbush
TipRanks · 12/09 13:36
Beam Therapeutics (BEAM) Receives a Buy from Wells Fargo
TipRanks · 12/09 11:56
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.